- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03380611
Algae and Cholesterol Absorption
Effects of Wakame and Spirulina Consumption on Intestinal Cholesterol Absorption in Non- Hypercholesterolemic Men and Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
Secondary objectives are to investigate the effects of wakame and spirulina consumption on fasting markers for lipid metabolism, glucose metabolism and blood pressure.
Study design:
This study is a double-blinded, randomized, placebo-controlled, crossover intervention trial consisting of three intervention periods of 17 days each, separated by a minimum washout period of 14 days.
Study population:
The study population will consist of 37 healthy, non-hypercholesterolemic men and women aged between 18 and 70 years.
Intervention:
All subjects will receive wakame, spirulina and placebo capsules in randomized order. Subjects will be asked to consume 12 capsules per day for 17 days, which is equal to 4.8 grams of wakame or spirulina a day.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229ER
- Maastricht University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged between 18 and 70 years;
- BMI between 18 and 30 kg/m2;
- Non-smoking;
- No elevated serum triacylglycerol concentrations (< 4.5 mmol/L);
- Willing to comply to the study protocol during the study;
- Agreeing to be informed about medically relevant personal test-results.
Exclusion Criteria:
- Not willing to abstain from any algae and/or seaweed consumption or algae/seaweed containing products two weeks before the start and during the trial;
- Use of plant-sterol/stanol-enriched foods (e.g. Becel Proactive) or supplements in the four weeks prior to the screening and/or during the study;
- Use of cholesterol or lipid-lowering medications (e.g. statins, bile-acid sequestrates, cholesterol absorption inhibitors);
- Use of any kind of medication or a medically prescribed diet, which can interfere with the study;
- Use of oral antibiotics in 40 days or less prior to the start of the study;
- Use of food supplements that might interfere with study measurements (judged by the principal investigator) in four weeks or less prior to the start of the study;
- Indications of treatment according to the Standard for Cardiovascular Risk Management from the Dutch General Practitioners community;
- Any medical condition that might interfere with study (measurements), judged by the principal investigator, including cardiovascular diseases or events (e.g. acute myocardial infarction or cerebro-vascular accident), diabetes, asthma, COPD, rheumatoid arthritis, and gastro-intestinal diseases (e.g. inflammatory bowel disease);
- Unstable body weight (weight gain or loss > 3 kg in the past 3 months);
- Females who are pregnant, breast feeding or who may wish to become pregnant during the study;
- Consumption of > 14 (males) or > 10 (females) alcoholic consumptions a week;
Reported intense sporting activities > 10 hours a week;
• Abuse of drugs;
- Participation in any other biomedical trial four weeks prior to the screening visit;
- Having donated >150 ml blood within 1 month prior to the screening visit, planning to donate blood during the study or within one month after finishing the study;
- Impossible or difficult to puncture as evidenced during the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Wakame
Subjects will receive capsules containing wakame
|
Consumption of 4.8 grams wakame per day for 17 days
Other Names:
|
EXPERIMENTAL: Spirulina
Subjects will receive capsules containing spirulina
|
Consumption of 4.8 grams spirulina per day for 17 days
Other Names:
|
PLACEBO_COMPARATOR: Control
Subjects will receive capsules containing microcrystalline cellulose
|
Consumption of microcrystalline cellulose for 17 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Markers for intestinal cholesterol absorption
Time Frame: Difference in outcomes between interventions and control at 17 days
|
Serum cholesterol-standardized campesterol concentrations will be measured as a marker for intestinal cholesterol absorption
|
Difference in outcomes between interventions and control at 17 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lipids
Time Frame: Difference in outcomes between interventions and control at 17 days
|
Several markers for fasting lipid metabolism, including total cholesterol, LDL cholesterol and HDL cholesterol, will be measured in blood samples
|
Difference in outcomes between interventions and control at 17 days
|
Markers for cholesterol synthesis
Time Frame: Difference in outcomes between interventions and control at 17 days
|
Serum cholesterol-standardized lathosterol and desmosterol concentrations will be measured as a markers for cholesterol synthesis
|
Difference in outcomes between interventions and control at 17 days
|
Glucose concentrations
Time Frame: Difference in outcomes between interventions and control at 17 days
|
Fasting plasma glucose concentrations will be determined
|
Difference in outcomes between interventions and control at 17 days
|
Blood pressure
Time Frame: Difference in outcomes between interventions and control at 17 days
|
Systolic and diastolic blood pressure will be determined
|
Difference in outcomes between interventions and control at 17 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- METC 17-3-022
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intestinal Cholesterol Absorption
-
Unilever R&DAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Completed
-
Canadian Collaborative Research NetworkGLOCK HEALTH, Science and Research, G.m.b.h.CompletedCholesterol AbsorptionUnited States
-
a2 Milk Company Ltd.Completed
-
KU LeuvenRecruitingMetabolism | Intestinal Absorption | Systemic Availability | Short-chain Fatty AcidsBelgium
-
Northumbria UniversityWithdrawnBlood Glucose | Appetite | Intestinal Absorption | Nutrient Sensing | Taste ReceptorsUnited Kingdom
-
Instituto de Investigación Sanitaria de la Fundación...Biopolis S.L.; Adventia PharmaUnknownMalnutrition | Crohn Disease | Absorption; Disorder | Absorption; Disorder, Protein | Absorption; Disorder, Fat | Absorption; Disorder, CarbohydrateSpain
-
KU LeuvenNot yet recruitingIron Absorption | Zinc Absorption
-
University of California, DavisNot yet recruitingIron Absorption | Zinc AbsorptionUnited States
-
Astellas Pharma Europe B.V.Cubist Pharmaceuticals LLCCompletedHealthy Subjects | Drug-Drug Interaction (DDI) | Intestinal Absorption | Pharmacokinetics of Rosuvastatin | Pharmacokinetics of FidaxomicinGermany
-
Malaysia Palm Oil BoardUniversity of MalayaCompleted
Clinical Trials on Wakame
-
University of BergenInstitute of Marine ResearchCompleted